Loading
A phase 3 trial of Elacestrant, Exemestane and Tamoxifen in advanced solid tumours, run by Stemline Therapeutics, Inc., now recruiting.
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence is a phase 3 interventional study registered as NCT06492616 by Stemline Therapeutics, Inc., with 4220 participants planned, started 2024-09-27 and due to reach its primary completion in 2029-08. Interventions recorded: Elacestrant, Anastrozole, Letrozole, Exemestane and Tamoxifen.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Exemestane, Tamoxifen, UCSF Helen Diller Family Comprehensive Cancer Center, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, UCSF Helen Diller Family Comprehensive Cancer Center, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Exemestane, Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Exemestane, Tamoxifen, UCSF Helen Diller Family Comprehensive Cancer Center, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/